Impact of Clazosentan Use on Symptomatic Vasospasm and Early Ambulation in Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Cohort Study.

ABSTRACT: This retrospective cohort study investigated the association between the use of clazosentan and the incidence of symptomatic vasospasm, as well as rehabilitation-related outcomes, particularly, the timing of ambulation, in patients with aneurysmal subarachnoid hemorrhage. A total of 153 patients who underwent surgical clipping or endovascular coiling at our institution between January 2020 and March 2025 were included; among them, 76 received clazosentan, and 77 received conventional treatment.The primary outcomes were the incidence of symptomatic vasospasm and the number of days to initial ambulation. Secondary outcomes included changes in body weight, peripheral oxygen saturation, and laboratory parameters one week after drug administration.The incidence of symptomatic vasospasm was sign

SUBMITTER: Suzuki S 

PROVIDER: S-EPMC12799342 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature